丙氨酸转氨酶和天冬氨酸转氨酶是反映HBeAg阴性慢性乙型肝炎肝组织炎性分级的敏感指标

目的 分析HBeAg阴性慢性乙型肝炎(CHB)自然病程中血清ALT和AST水平,以及由相同肝实质细胞体积分摊的血清ALT和AST水平与肝组织炎症活动度分级的关系.方法 检测HBeAg阴性CHB患者肝组织病理学不同炎症活动度分级患者血清ALT和AST水平,以及相同肝实质细胞体积分摊的血清ALT和AST水平.数据经ANOVA检验.结果 145例CHB肝组织炎症活动度分级G1～G4级患者血清ALT水平分别为(35.3±29.1)、(91.6±120.4)、(111.6±116.1)和(118.0±122.1)U/L,用相同肝脏实质细胞体积分摊后的血清ALT水平分别为(54.0±45.1)、(144.2±184.9)、(191.3±204.8)和(215.1±226.5)U/L,G1级分别与G2～G4两两比较,差异有统计学意义(P＜0.05);G1～G4的AST水平分别为(35.5±29.0)、(64.9±71.7)、(96.0±81.9)和(102.8±77.0)U/L,相同肝脏实质细胞体积分摊后的血清AST水平分别为(54.3±44.6)、(102.3±107.9)、(165.2±148.7)和(189.4±145.4)U/L,G1与G3、G1与G4、G2与G3、G2与G4比较,差异有统计学意义(P＜0.05).结论 HBeAg阴性CHB自然病程中,ALT和AST均是反映肝组织炎症活动度分级严重性的较为敏感的指标.

Abstract：

Objective To investigate the relationship between serum levels of alanine aminotransferase (ALT)or aspartate aminotransferase (AST)apportioned by the same hepatic parenchyma cell volume and liver histological necroinflammation grades in HBeAg-negative chronic hepatitis B (CHB)patients.Methods A total of 145 CHB patients were divided into four groups:Gl,G2,G3 and G4 based on the liver histological necroinflammation grade.The serum ALT and AST levels were determined by automatic biochemical instrument in these four groups.Furthermore,serum ALT and AST levels were then apportioned by the same hepatic parenchyma cell volume.The data were analyzed by ANOVA.Results Mean serum ALT levels in G1,G2,G3 and G4 groups were (35.3±29.1),(91.6±120.4),(111.6± 116.1)and (118.0±122.1)U/L,respectively,and the serum ALT levels apportioned by same hepatic parenchyma cell volume were ( 54.0 ± 45.1 ),( 144.2 ± 184.9 ),(191.3± 204.8)and (215.1 ± 226.5)U/L,respectively.The pairwise comparison between G1 and other three groups all showed statistically significant difference (P＜0.05).Meanwhile,AST levels in G1 to G4 groups were (35.5± 29.0),(64.9±71.7),(96.0±81.9)and (102.8±77.0)U/L,respectively and the serum AST levels apportioned by the same hepatic parenchyma cell volume were (54.3±44.6),(102.3± 107.9),(165.2±148.7)and (189.4±145.4)U/L,respectively.The pairwise comparison between G1 and G3,G1 and G4,G2 and G3,G2 and G4 all showed statistically significant difference (P＜0.05).Conclusion Both AST and ALT levels are sensitive indicators for liver inflammation grading in HBeAg-negative CHB patients during the natural history of the disease.

Alanine aminotransferase and aspartate aminotransferase levels are sensitive indicators for liver inflammation grading in HBeAg-negative chronic hepatitis B patients

Objective To investigate the relationship between serum levels of alanine aminotransferase (ALT)or aspartate aminotransferase (AST)apportioned by the same hepatic parenchyma cell volume and liver histological necroinflammation grades in HBeAg-negative chronic hepatitis B (CHB)patients.Methods A total of 145 CHB patients were divided into four groups:Gl,G2,G3 and G4 based on the liver histological necroinflammation grade.The serum ALT and AST levels were determined by automatic biochemical instrument in these four groups.Furthermore,serum ALT and AST levels were then apportioned by the same hepatic parenchyma cell volume.The data were analyzed by ANOVA.Results Mean serum ALT levels in G1,G2,G3 and G4 groups were (35.3±29.1),(91.6±120.4),(111.6± 116.1)and (118.0±122.1)U/L,respectively,and the serum ALT levels apportioned by same hepatic parenchyma cell volume were ( 54.0 ± 45.1 ),( 144.2 ± 184.9 ),(191.3± 204.8)and (215.1 ± 226.5)U/L,respectively.The pairwise comparison between G1 and other three groups all showed statistically significant difference (P＜0.05).Meanwhile,AST levels in G1 to G4 groups were (35.5± 29.0),(64.9±71.7),(96.0±81.9)and (102.8±77.0)U/L,respectively and the serum AST levels apportioned by the same hepatic parenchyma cell volume were (54.3±44.6),(102.3± 107.9),(165.2±148.7)and (189.4±145.4)U/L,respectively.The pairwise comparison between G1 and G3,G1 and G4,G2 and G3,G2 and G4 all showed statistically significant difference (P＜0.05).Conclusion Both AST and ALT levels are sensitive indicators for liver inflammation grading in HBeAg-negative CHB patients during the natural history of the disease.